The European Medicines Agency's committee has recommended approval of French drugmaker Sanofi's first-of-its-kind drug that ...

During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new ...

Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetesRecommendation based on the TN-10 study, ...

A recently launched campaign starring patients and scientists shows Sanofi in hot pursuit of scientific innovation. | A ...

Sanofi is rolling out a new global campaign that features the stories of six real patients, to underscore its core purpose.

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug ...

Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...

Sanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product” assets. The French drugmaker axed Sjögren’s syndrome from the list of targeted indications for ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

Sanofi has cited security concerns about planned highrises near its plant, while the developer says the provincial order ...

Sanofi Consumer Healthcare India Limited said on Thursday that its third-quarter profit jumped 40% to ₹62.9 crore and revenue ...

In November 2025, SOE Medical Procurement of Ukraine renegotiated the managed entry agreements (MEAs) with the international ...